AlmirallDLizotteDMurphySA. SMART design issues and the consideration of opposing outcomes. Discussion of ‘Evaluation of viable dynamic treatment regimes in a sequentially randomized trial of advanced prostate cancer’ by Wang, Rotnitzky, Lin, Millikan, and Thall. J Am Stat Assoc2012; 107: 509–12 (PMCID: PMC3607391).
2.
ChakrabortyBLaberBZhaoY. Inference for optimal dynamic treatment regimes using an adaptive m-out-of-n bootstrap scheme. Biometrics2013; 69(3): 714–23 (PMCID: PMC3864701).
3.
GalloPChuang-SteinCDragalinV. Adaptive designs in clinical drug development – An executive summary of the PhRMA working group. J Biopharm Stat2016; 16: 275–83 (PMID 16724485).
StadlerWM. The randomized discontinuation trial: A phase II design to assess growth-inhibitory agents. Mol Cancer Ther2007; 6: 1180–85 (PMID 17431101).
10.
WangLRotnitzkyALinXMillikanREThallPF. Evaluation of viable dynamic treatment regimes in a sequentially randomized trial of advanced prostate cancer. J Am Stat Assoc2012; 107(498): 493–508 (PMCID PMC3433243).
11.
BinkleyN1HarkeJKruegerD. Vitamin K treatment reduces undercarboxylated osteocalcin but does not alter bone turnover, density, or geometry in healthy postmenopausal North American women. J Bone Miner Res2009; 24(6): 983–91 (PMCID: PMC2684650).